Risperdal Gynecomastia Plaintiff Awarded $500,000 in Fourth Trial
A third Risperdal gynecomastia plaintiff has been awarded a half million dollars, following the conclusion of another trial in Pennsylvania. According to a report from The Legal Intelligencer, the 12-member jury deliberated for just six hours before finding that Janssen Pharmaceuticals negligently failed to warn patients about the drug’s association with male breast growth, and that the negligence caused the plaintiff to develop the condition.
The lawsuit had been filed on behalf of a young man who was treated with Risperdal for three years starting in 2006, when he was just 11-year-old. The drug had been prescribed to combat symptoms associated with Tourette’s syndrome, an indication for which Risperdal has never been approved. Within a year of initiating treatment, he had experienced excessive breast growth. When he was 18, the plaintiff underwent surgery to remove the excess tissue.
The lawsuit had alleged that Janssen and its parent, Johnson & Johnson, concealed Risperdal’s association with male breast growth. The companies were also accused of improperly marketing the drug for unapproved, off-label use in children.
The jury delivered a unanimous decision on the plaintiff’s failure to warn and damages claims. But two members of the panel found for Janssen on causation.
Other Risperdal Damage Awards
The verdict was the fourth delivered this year in a mass tort litigation established in the Philadelphia Court of Common Pleas for product liability claims involving alleged Risperdal side effects. In all four trials, juries have found that gynecomastia warnings provided to patients and doctors by the drug’s manufacturers were inadequate. Two earlier trials ended with $2.5 million and $1.75 million judgments for the plantiffs. No damages were awarded in the remaining trial, as the jury was unable to conclude that Risperdal had actually caused the plaintiff’s male breast growth.
According to The Legal Intelligencer, the relatively low damage award in this latest case did not surprise the plaintiff’s attorneys.
“Everyone knew going into this case that the compensatory damages were modest,” one of the lawyers said. “The verdict seems to me to be in line.”
Obtain a Risperdal Case Review
Bernstein Liebhard LLP continues to offer free, no obligation case reviews to individuals who may have experienced gynecomastia while using Risperdal. To learn more, please call 877-779-1414 to get in touch with one of our attorneys.